United Therapeutics CEO Martine Rothblatt Sold About $2.2M in March 2026 as UTHR Sat Near Record Results
United Therapeutics CEO Martine Rothblatt sold roughly $2.2 million of UTHR stock across visible March 2026 Form 4 sale lines. The trades landed after the company reported record 2025 revenue and while UTHR still traded at $580.51 on April 17, 2026.
United Therapeutics CEO Martine Rothblatt sold stock in a series of visible March 2026 Form 4 lines totaling roughly $2.2 million. Those sales came after UTHR reported record full-year 2025 revenue and while the stock was still trading at $580.51 on April 17, 2026. That combination makes the filing notable, but not automatically bearish.
TL;DR
- Seller: Martine Rothblatt, Chairperson and CEO of United Therapeutics.
- Approx. sale value: about $2.2M across the visible March 2026 sale lines.
- Business backdrop: United Therapeutics reported record 2025 revenue of $3.18B.
- Why investors care: Rothblatt is closely tied to the company’s strategic identity and long-term growth narrative.
- Stock context: UTHR was at $580.51 on April 17, 2026.
Transaction Snapshot
| Window | Insider | Action | Approx. value | Why readers care |
|---|---|---|---|---|
| March 12-16, 2026 | Martine Rothblatt | Exercise-related sales | ~$2.2M | The transactions landed right after a record revenue year and ahead of additional long-term catalysts. |
Why The Market Cares Now
United Therapeutics reported full-year 2025 revenue of about $3.18 billion, up 11% from 2024, and fourth-quarter revenue of $790.2 million. The company highlighted another year of record total revenue, strong Tyvaso growth, and management commentary about potential transformational clinical readouts. It also disclosed share repurchase activity through accelerated repurchase agreements totaling roughly $2.0 billion in aggregate across the two programs discussed in the release. In other words, Rothblatt sold into a business story that still looked fundamentally strong.
What The Filing Probably Means
The visible pattern reads more like exercise-related monetization than a sudden vote against the company. The latest sales were relatively small compared with Rothblatt’s historical relevance to United Therapeutics, and the broader ownership picture still included beneficial ownership signals in company-related 13G filings. Investors should be careful not to flatten a nuanced founder-CEO ownership story into a one-line “sold stock” headline.
What To Watch Next
The follow-up question is whether the selling remains isolated and mechanical while United Therapeutics keeps delivering on Tyvaso growth and future clinical milestones. If the company’s operating story remains intact, this filing is more likely to be viewed as routine executive liquidity inside a still-constructive fundamental backdrop.
Q&A
How much UTHR did Martine Rothblatt sell?
Based on the visible March 2026 sale lines, roughly $2.2 million.
What was the business backdrop?
United Therapeutics had just reported record full-year 2025 revenue of $3.18 billion.
What was UTHR trading at later?
UTHR was at $580.51 on April 17, 2026.
Related Coverage
Related Research
Explore all researchCalPERS used Q4 2025 to keep broad-market exposure high through VOO while still adding to Nvidia, Microsoft, Alphabet and Broadcom. The next filing will show whether the pension giant keeps that simple beta-heavy structure or rotates again.
Apr 17, 2026
Raymond James used Q4 2025 to keep broad ETF exposure high through VOO, AGG, SPY and IEFA while also adding to sector sleeves such as XLK and XLE. The next filing will show whether that balanced ETF-heavy structure remains the preferred setup.
Apr 17, 2026
Janus Henderson kept Nvidia and Microsoft on top in Q4 2025, but the more interesting signal was underneath: new exposure to Intuitive Surgical, Protagonist Therapeutics and other growth-healthcare names. The next filing will show whether that rotation keeps building.
Apr 17, 2026
Fisher’s Q4 2025 filing was still packed with mega-cap tech, but the bigger tell was a giant Treasury and investment-grade corporate bond sleeve built through IEF and VCIT. The next filing will show whether that duration bet was tactical or structural.
Apr 17, 2026
Dodge & Cox’s Q4 2025 filing barely moved on headline AUM, but the underlying changes were more interesting: fresh positions in Brookfield, TransUnion and PDD inside a still-diversified value book. The next filing will show whether those adds were conviction moves or just incremental reshuffling.
Apr 17, 2026